New combo tackles tough lung cancer
NCT ID NCT04141644
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding the immunotherapy drug ipilimumab (Yervoy) to the targeted therapy osimertinib (Tagrisso) is safe and tolerable for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study involves 24 adults whose cancer is stable on osimertinib alone. Researchers will monitor side effects and look for early signs that the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib (Tagrisso) and ipilimumab (Yervoy)
- What this could lead to
- If it works, this combination could offer a new treatment option for people with EGFR-mutated lung cancer whose disease is stable on osimertinib alone.
- What could go wrong
- This is a very early (phase 1), small trial with only 24 participants. The main goal is safety, not proof of effectiveness. Combining these drugs may cause significant side effects, and the benefit may be limited or not confirmed in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States